Dr. Charles Haynes is a Professor and Tier I Canada Research Chair in Interfacial Biotechnology within the Michael Smith Laboratories and the Department of Chemical and Biological Engineering of the University of British Columbia. The central objective of Dr. Haynes’ research program is to improve our understanding of the interfacial and binding-recognition behavior of biomolecules and cellular systems, and to use this fundamental knowledge to invent new technologies and instruments for isolating and analyzing biological analytes from complex samples.
Dr. Haynes has pioneered and licensed a number of technologies to efficiently localize, purify, or analyze biomolecules that have achieved widespread use in the biotechnology industry. These include the Fractogel™ line of chromatography media (now sold by Merck KgA), controlled-shear affinity filtration technology for cell-culture-derived monoclonal antibody purification (licensed to Pall Corp.), and TEMPlex™ technology, a system that removes a former bottleneck in high-throughput DNA sequencing that was used by Celera Genomics Inc. in their landmark program to sequence the human genome. More recently, Dr. Haynes' research has focused on developing novel technology for biomarkers detection in source waters, drinking waters and clinical samples, including microfluidic systems for monoclonal antibody discovery and characterization, as well as improved qPCR and digital PCR-based methods for identifying and quantifying rare or mutant genes that are reliable indicators of the presence of pathogenic or viral adulterants in aqueous samples or of life-threatening diseases, including a range of cancers. Dr. Haynes is a Fellow of the Royal Society of Canada, and recipient of several awards, including the Winnaker Technology Transfer Award, the Overbeek Medal, and the Merck Bioseparation Sciences Award.